Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Abstrakt

Brief Analysis on Intravenous Immunoglobulin Treatment

Richas Carlo NM

Worldwide, the coronavirus 2 causing severe acute respiratory syndrome has infected and killed an alarming number of people. For the coronavirus illness of 2019 (COVID-19), no particular treatment has been internationally standardised; nevertheless, intravenous immunoglobulin (IVIG) has occasionally been utilised as adjuvant therapy in critically ill patients with COVID-19 pneumonia. We describe a case of a 50-year-old man who had severe COVID-19 pneumonia and had received an adjuvant 5-day IVIG regimen. We avoided using intrusive respiratory support. The patient made a full recovery and was released from the hospital without additional oxygen. Patients with severe COVID-19 pneumonia may have an improved chance of survival with a large IVIG dose. We looked at research on how IVIG use might help the early stages of the disease in the current report.